Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upgrading its current co-marketing ...

The primary outcome measure in PUNCH CD 3 is the proportion of patients with recurrent C. diff infection within eight weeks of starting treatment with either RBX2660 or placebo. Patients will be ...

The study, published Sept. 30 in Open Forum Infectious Diseases, analyzed 45,049 patient records from 779 hospitals of adults who received treatment for C. diff infections before and after 2021.

The use of fidaxomicin for Clostridioides difficile infection (CDI) has increased significantly since 2021 but it ... which is the most common healthcare-associated infection in adults and affects an ...

Expert Rev Anti Infect Ther. 2010;8(10):1113-1119.

Nurses and nurse midwives have historically considered patient education one of their most important responsibilities. Increasingly, however, appropriate and comprehensive patient education has ...

Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the ...

The best free PDF editor offers all the tools you'd expect from premium editors - but you won't need to pay anything. We've tested over twenty top apps, and this is the free PDF editing software ...

Oct. 2, 2024 — Despite growing evidence of the importance of student well-being and an abundance of best practices, most institutions have yet to prioritize it as much as they do enrollment ...

The news that State Superintendent of Education Ellen Weaver has now invited the atrocious content of "PragerU" (which, understand, has nothing at all to do with any actual educational entity ...

In everyday conversations, people tend to meander when they speak rather than stick to an agenda. They may want to connect and get to know others before volunteering a view or experience. And how they ...